Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Weekly call options eye rally in J.C. Penney Company, Inc. (JCP) ahead of New Year

Page 1 of 2

Weekly call options eye rally in J.C. Penney Company, Inc. (JCP) ahead of New YearJ.C. Penney Company, Inc. (NYSE:JCP) – Upside call buying in weekly options on J.C. Penney Company, Inc. (NYSE:JCP) this morning suggest some traders are positioning for shares in the department store operator to rally during the final week of the year. Shares in J.C. Penney Company, Inc. (NYSE:JCP) are up 2.65% at $20.11 as of 11:05 a.m. in New York, but are down more than 40% since the start of 2012. Fresh interest in weekly calls looks for shares in the retailer to extend this morning’s gains when the market reopens after the Christmas holiday. Volume is heaviest at the Dec. 28 ’12 $20 strike, where upwards of 3,500 calls changed hands against open interest of 1,469 contracts. It looks like most of the volume was purchased for an average premium of $0.68 each in the early going. In-the-money call buyers stand ready to profit at expiration this week should shares in J.C. Penney Company, Inc. (NYSE:JCP) rally another 2.8% to top the average breakeven price of $20.68. Bullish positioning spread to the Dec. 28 ’12 $20.5 and $21 strikes, with more than 650 contracts purchased at each strike for average premiums of $0.45 and $0.28 apiece, respectively. Finally, around 275 of the Dec. 28 ’12 $22 strike calls were picked up at an average premium of $0.20 each, thus positioning buyers to profit in the event of a more than 10% move in the share price to $22.20 by expiration.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) – Shares in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) fell sharply in after-hours trading on Friday after the company said the U.S. Food and Drug Administration needs more time to complete its review of Raptor’s New Drug Application (NDA) for RP103 (PROCYSBI™), a potential treatment for nephropathic cystinosis, according to a press release issued by Raptor on Friday. Shares continue to slide on Monday morning, down 7% at $5.34 as of 11:25 a.m. ET. One or more traders preparing for Raptor’s shares to continue to slide in the New Year snapped up put options in the February expiry. Traders exchanged more than 750 puts at the Feb. $5.0 strike against previously existing open interest of 271 contracts. It looks like most of the downside puts were purchased for an average premium of $0.19 apiece. Put buyers stand ready to profit in the event that Raptor’s shares decline another 10% from the current price of $5.34 to breach the average breakeven point at $4.81 by February expiration. Shares in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last traded below $4.81 at the end of November.

Page 1 of 2
Loading Comments...